Dihexa

Overview

Dihexa’s reputation rests almost entirely on preclinical data from Washington State University, where it demonstrated extraordinary potency in reversing cognitive deficits in aged rodents. The claim that it is 7 orders of magnitude more potent than BDNF at promoting functional synaptic connections, if replicated, would make it pharmacologically remarkable.

The c-Met Safety Concern

The mechanism — HGF/c-Met pathway activation — is a significant safety concern. c-Met is a proto-oncogene; mutations that constitutively activate c-Met are found in numerous cancers, and pharmaceutical companies spend enormous resources developing c-Met inhibitors to treat malignancies. Activating this pathway therapeutically creates obvious theoretical cancer risk.

No Human Data

There are zero completed human trials for dihexa. All evidence is in vitro or rodent. The translation from rodent cognitive enhancement to human cognitive benefit is not established, and the safety profile in humans is completely unknown.

Research Context

Despite the preclinical excitement, dihexa has not advanced beyond animal studies after more than a decade. This stalling is concerning — if the data were as compelling as claimed, clinical development would be expected to proceed. The c-Met oncology risk may be deterring pharmaceutical investment.